Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program
Tara C. Gangadhar(University of Pennsylvania), April K.S. Salama(Duke University), Michael A. Postow(Memorial Sloan Kettering Cancer Center), Adil Daud(University of California, San Francisco), Debra Kush(Merck & Co., Inc., Rahway, NJ, USA (United States)), Mihaela Gazdoiu(Novartis (Switzerland)), Roxana Dronca(Dana-Farber Cancer Institute), Omid Hamid(Cedars-Sinai Medical Center), Richard W. Joseph(Daiichi Sankyo (United States)), Wen-Jen Hwu(The University of Texas MD Anderson Cancer Center), Anna C. Pavlick(Cornell University), Steven O’Day(Saint John's Health Center), Romina P. Oxborough(University of California, San Francisco), F. Stephen Hodi(Harvard University), Harriet M. Kluger(Yale Cancer Center), Aiming Yang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 18
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k